Related Experiment Videos
Who's on third? Regulation of third-party genetic interpretation services
Christi J Guerrini1, Jennifer K Wagner2, Sarah C Nelson3
1Baylor College of Medicine, Center for Medical Ethics and Health Policy, Houston, TX, USA. guerrini@bcm.edu.
Summary
Third-party genetic interpretation services offer insights but raise accuracy and privacy concerns. Federal agencies could potentially regulate these services, clarifying oversight for genetic data interpretation.
Area of Science:
- Genetics
- Bioethics
- Regulatory Science
Background:
- Third-party genetic interpretation services are increasingly used to understand raw genetic data.
- These services offer various applications, from ancestry matching to health risk assessments.
- Concerns regarding accuracy, safety, and privacy practices are growing.
Purpose of the Study:
- To analyze the potential federal regulatory oversight of third-party genetic interpretation services.
- To clarify regulatory uncertainties surrounding these emerging services.
- To assess the applicability of existing frameworks from key US agencies.
Main Methods:
- Examination of regulatory frameworks of four US agencies: CMS, FDA, HHS OCR, and FTC.
- Analysis of their historical involvement in regulating genetic testing and information.
- Assessment of the scope of federal jurisdiction over third-party genetic interpretation.
Main Results:
- Existing US regulatory agencies have potential, albeit limited, jurisdiction over third-party genetic interpretation services.
- Current regulatory approaches by agencies like the FDA and FTC may apply.
- Uncertainty exists due to the lack of explicit official positions from regulatory bodies.
Conclusions:
- Federal oversight of third-party genetic interpretation services is potentially appropriate.
- Clarification of agency roles and responsibilities is needed.
- Appropriate exercise of oversight can address accuracy, safety, and privacy concerns.